The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
If I remember correctly, the regulator specified the use of Demasys as placebo, having said that ....not a simple substance, so a bit of investigation to eliminate any potential problem, would not have come amiss.
I don't doubt that parties putting money in have personally tried it...why wouldn't they ? Bearing this in mind...massive vote of confidence.
FDA requirements are likely to be
Considerably relaxed, due to data available from previous trial.
Simon Thompson of IC may well be commenting favourably in next issue.
Is 1million a 'bargain' or is it a ludicrously low valuation ?
Would someone wih more knowledge than myself of company market valuations particularly pharmaceutical take a view, based on realistic estimates of likely market size, sales, profit, EPR etc ?
RNS7182X 20.12.19
ADDITIONAL INFORMATION
'Dermasys is a proprietary patented drug delivery technology platform.
------------------------------------------------------------------------------
It is a clear odourless gel that provides rapid and targeted local delivery to the required site of action.'
This is clearly reference to carrier only not medicated gel
MED was not/ is not flawed; Dermasys was not/is not flawed. What was flawed beyond belief was the trial protocol...effectively there was NO placebo.
The trial regulators inexplicably specified Dermasys with knowledge of ilts design purpose ...knowing it had a mechanical action.
FUM, beggaring belief accepted, well aware that the 'placebo' was a substance penetrating to the vascular level ...which should have given pause for thought and a half day's work with some simple tests.
Surely anyone with intelligence/commonsense should have been wary.
I would have thought-probably wrongly, that in the circumstances, the regulatory authorities would be keen to 'oil the wheels' to enable further progress
I
I would not be expecting ST to comment in any detail on the technical aspects or endorse the product but my thought is that in surveying the situation, the tone of his aricle (assuming there is one), might well influence (one way or the other ) sh level of confidence in bod and their handling of the situation.